The Impact of the COVID-19 Pandemic on Incidence and Short-Term Survival for Common Solid Tumours in the United Kingdom: A Cohort Analysis
DOI: https://doi.org/10.2147/clep.s463160
2024-06-12
Clinical Epidemiology
Abstract:Nicola L Barclay, 1 Theresa Burkard, 1 Edward Burn, 1 Antonella Delmestri, 1 Andrea Miquel Dominguez, 2 Asieh Golozar, 3 Carlos Guarner-Argente, 4 Francesc Xavier Avilés-Jurado, 5 Wai Yi Man, 1 Àlvar Roselló Serrano, 6 Andreas Weinberger Rosen, 7 Eng Hooi Tan, 1 Ilona Tietzova, 8 Daniel Prieto Alhambra, 1, 9 Danielle Newby 1 On behalf of the OPTIMA Consortium 1 Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom; 2 Otorrinolaringology department, Hospital Joan XXIII de Tarragona, Tarragona, Spain; 3 Odysseus Data Services, Cambridge, MA, USA; 4 Gastroenterology Department, Hospital de la Santa Creu I Sant Pau, Universitat Autònoma de Barcelona, Sant Quintí, Barcelona, Spain; 5 Head Neck Tumors Unit, Hospital Clínic de Barcelona, Universitat de Barcelona, Barcelona, Spain; 6 Institut Català d'Oncologia, Hospital Universitari Dr Josep Trueta, Girona, Spain; 7 Centre for Surgical Science, Department of Surgery, Zealand University Hospital, Koege, Denmark; 8 First Department of Tuberculosis and Respiratory Diseases, First Faculty of Medicine, Charles University, Prague, Czech Republic; 9 Department of Medical Informatics, Erasmus University Medical Centre, Rotterdam, the Netherlands Correspondence: Daniel Prieto Alhambra, Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, OX3 7LD, United Kingdom, Email Purpose: The COVID-19 pandemic profoundly affected healthcare systems and patients. There is a need to comprehend the collateral effects of the pandemic on non-communicable diseases. We examined the impact of the pandemic on short-term survival for common solid tumours, including breast, colorectal, head and neck, liver, lung, oesophageal, pancreatic, prostate, and stomach cancer in the UK. Methods: This was a population-based cohort study of electronic health records from the UK primary care Clinical Practice Research Datalink GOLD database. In sum, 12,259,744 eligible patients aged ≥ 18 years with ≥ 1 year's history identified from January 2000 to December 2022 were included. We estimated age-standardised incidence and short-term (one- and two-year) survival for several common cancers from 2000 to 2019 (in five-year strata) and compared these to 2020– 2022 using the Kaplan–Meier method. Results: Incidence decreased for most cancers in 2020 and recovered to different extents in 2021– 2022. Short-term survival improved for most cancers between 2000 and 2019, but then declined, albeit minimally, for those diagnosed in 2020– 2022. This was most pronounced for colorectal cancer, with one-year survival falling from 78.8% (95% CI 78%– 79.6%) in 2015– 2019 to 77% (95% CI 75.6– 78.3%) for those diagnosed in 2020– 2022. Conclusion: Short-term survival for many cancers was impacted, albeit minimally, by the pandemic in the UK, with reductions in survivorship from colorectal cancer equivalent to returning to the mortality seen in the first decade of the 2000s. While data on longer-term survival are needed to fully comprehend the impact of COVID-19 on cancer care, our findings illustrate the need for an urgent and substantial commitment from the UK National Health Service to address the existing backlog in cancer screening and diagnostic procedures to improve cancer care and mortality. Keywords: cancer, COVID-19, colorectal cancer, incidence, pandemic, survival The COVID-19 pandemic left a permanent mark on global public health, with profound implications for healthcare systems and patients. Whilst healthcare systems grappled with the overwhelming demands of treating COVID-19 patients, there emerged a pressing need to comprehend the collateral effects of the pandemic on non-communicable diseases, including cancer. Social restrictions and the prioritisation of urgent over elective healthcare provision imposed by the pandemic impacted screening and diagnostic pathways for many cancers worldwide. 1–3 Reduced screening and diagnostic tests inevitably cause delays, leading to more advanced stage at diagnosis and worsened prognosis. Survival from cancer has generally improved over the last two decades, with combined mortality rates across all cancers and sexes decreasing by around 10%. 4 One study estimated that in the UK, the probability of dying from cancer before 80 years of age declined from 0.16 to 0.13 for women and 0.22 to 0.17 for men across 2002–2019. 5 The impro -Abstract Truncated-
public, environmental & occupational health